The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Warner
Juliet L
JL
D001559:Benzhydryl Compounds / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003408:Cresols / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D018727:Muscarinic Antagonists / Q000191:economics* / Q000627:therapeutic use; D010665:Phenylpropanolamine / Q000191:economics* / Q000627:therapeutic use; D000068737:Tolterodine Tartrate; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000191:economics
D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate